Borden Lacy
Last active: 3/24/2020

  1. Use of a neutralizing antibody helps identify structural features critical for binding of toxin TcdA to the host cell surface. Kroh HK, Chandrasekaran R, Rosenthal K, Woods R, Jin X, Ohi MD, Nyborg AC, Rainey GJ, Warrener P, Spiller BW, Lacy DB (2017) J Biol Chem 292(35): 14401-14412
    › Primary publication · 28705932 (PubMed) · PMC5582835 (PubMed Central)
  2. The role of toxins in Clostridium difficile infection. Chandrasekaran R, Lacy DB (2017) FEMS Microbiol Rev 41(6): 723-750
    › Primary publication · 29048477 (PubMed) · PMC5812492 (PubMed Central)
  3. Integrated, High-Throughput, Multiomics Platform Enables Data-Driven Construction of Cellular Responses and Reveals Global Drug Mechanisms of Action. Norris JL, Farrow MA, Gutierrez DB, Palmer LD, Muszynski N, Sherrod SD, Pino JC, Allen JL, Spraggins JM, Lubbock AL, Jordan A, Burns W, Poland JC, Romer C, Manier ML, Nei YW, Prentice BM, Rose KL, Hill S, Van de Plas R, Tsui T, Braman NM, Keller MR, Rutherford SA, Lobdell N, Lopez CF, Lacy DB, McLean JA, Wikswo JP, Skaar EP, Caprioli RM (2017) J Proteome Res 16(3): 1364-1375
    › Primary publication · 28088864 (PubMed)
  4. Functional defects in TcdB toxin uptake identify CSPG4 receptor-binding determinants. Gupta P, Zhang Z, Sugiman-Marangos SN, Tam J, Raman S, Julien JP, Kroh HK, Lacy DB, Murgolo N, Bekkari K, Therien AG, Hernandez LD, Melnyk RA (2017) J Biol Chem 292(42): 17290-17301
    › Primary publication · 28842504 (PubMed) · PMC5655507 (PubMed Central)
  5. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab. Hernandez LD, Kroh HK, Hsieh E, Yang X, Beaumont M, Sheth PR, DiNunzio E, Rutherford SA, Ohi MD, Ermakov G, Xiao L, Secore S, Karczewski J, Racine F, Mayhood T, Fischer P, Sher X, Gupta P, Lacy DB, Therien AG (2017) J Mol Biol 429(7): 1030-1044
    › Primary publication · 28232034 (PubMed) · PMC7373199 (PubMed Central)
  6. Clostridium difficile toxin glucosyltransferase domains in complex with a non-hydrolyzable UDP-glucose analogue. Alvin JW, Lacy DB (2017) J Struct Biol 198(3): 203-209
    › Primary publication · 28433497 (PubMed) · PMC5534367 (PubMed Central)
  7. Antibacterial photosensitization through activation of coproporphyrinogen oxidase. Surdel MC, Horvath DJ, Lojek LJ, Fullen AR, Simpson J, Dutter BF, Salleng KJ, Ford JB, Jenkins JL, Nagarajan R, Teixeira PL, Albertolle M, Georgiev IS, Jansen ED, Sulikowski GA, Lacy DB, Dailey HA, Skaar EP (2017) Proc Natl Acad Sci U S A 114(32): E6652-E6659
    › Primary publication · 28739897 (PubMed) · PMC5559000 (PubMed Central)
  8. Exploiting dominant-negative toxins to combat Staphylococcus aureus pathogenesis. Reyes-Robles T, Lubkin A, Alonzo F, Lacy DB, Torres VJ (2016) EMBO Rep 17(3): 428-40
    › Primary publication · 26882549 (PubMed) · PMC4772982 (PubMed Central)
  9. Exploiting dominant-negative toxins to combat Staphylococcus aureus pathogenesis. Reyes-Robles T, Lubkin A, Alonzo F, Lacy DB, Torres VJ (2016) EMBO Rep 17(5): 780
    › Primary publication · 27139260 (PubMed) · PMC5341525 (PubMed Central)
  10. Crystal structure of Clostridium difficile toxin A. Chumbler NM, Rutherford SA, Zhang Z, Farrow MA, Lisher JP, Farquhar E, Giedroc DP, Spiller BW, Melnyk RA, Lacy DB (2016) Nat Microbiol : 15002
    › Primary publication · 27571750 (PubMed) · PMC4976693 (PubMed Central)